08 Nov 2018

VIVA 2018: BTG SENTRY BIOCONVERTIBLE IVC FILTER STUDY SHOWS FLAWLESS PERFORMANCE

  BTG plc highlighted the presentation of the two-year results for the SENTRY Trial at the Vascular Interventional Advances (VIVA) conference in Las Vegas. The prospective, multicenter trial of the BTG Sentry, the world’s first bioconvertible IVC filter, found that in addition to providing protection against pulmonary embolism (PE) during the

0